UWGI faculty, Drs.
are among a group of researchers
who will participate in prestigious, highly competitive U54 grants recently awarded from the National Cancer Institute that will
support the Barrett’s Esophagus Translational Research Network (BETRNet). BETRNet consists of four multi-institutional,
transdiciplinary, translational research centers and one coordinating center, all collaborating to develop an understanding of the basis of Barrett’s
esophagus and its conversion to esophageal carcinoma. Researchers will also work to determine the role genetics and
environmental factors play in the development and progression of these diseases, with the ultimate goal of reducing
the mortality associated with this deadly cancer.
Drs. William Grady and Andrew Kaz will participate in the 5-year
, $5.4M BETRNet grant awarded to the Case Comprehensive
Cancer Center and Case Western Reserve University, led by Principal Investigator,
Dr. Amitabh Chak
Dr. Grady, who serves as Co-Principal Investigator on the project, will be assessing, along with Dr. Kaz, the use of epigenetic alterations,
specifically methylated genes, as biomarkers for the early detection of Barrett’s esophagus and for monitoring the response
to treatment of Barrett’s esophagus with radiofrequency ablation.
“Dr. Chak has assembled a world-class group of investigators,” said Grady. “I am honored to be a part of this group,
and I am looking forward to the progress we will make in understanding and treating Barrett’s esophagus.”
Drs. John Inadomi and Jason Dominitz will participate in the 5-year, $5.8M BETRNet grant awarded to the University of Michigan,
led by Principal Investigators, Dr. David Beer and Dr. Thomas Wang
and the University of Washington, led by Principal Investigator, Dr. Eric Seibel
. Research conducted by this center will focus on multi-spectral targeted imaging for the early detection of
cancer in Barrett's esophagus. Dr. Dominitz will serve as a consultant on this project, and Dr. Inadomi will be conducting
comparative effectiveness research to determine the incremental value of using this novel technology to image neoplasia
associated with Barrett's esophagus. With the current emphasis on endorsing strategies that produce benefit in an environment
with resource constraints, Dr. Inadomi will also conduct formal cost-effectiveness analyses of this innovative strategy compared
with current care.
The BETRNet overall objective is to achieve a better understanding of esophageal adenocarcinoma (EA) biology, improve EA cancer
risk stratification and prediction, provide strategies for EA prevention, and better define individuals at risk.